Article
Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX…
OncoTargets and Therapy · 2021 · Wang KX, Cui TY, Yang XD, Wang GQ, Jiang QS, Sun H, Jiang NY, Yong XM, Shi CB, Ding YB, Chen XF, Fang YY
Key facts
| Title | Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial |
|---|---|
| First author | Wang KX, Cui TY, Yang XD, Wang GQ, Jiang QS, Sun H, Jiang NY, Yong XM, Shi CB, Ding YB, Chen XF, Fang YY |
| Journal | OncoTargets and Therapy |
| Published | Sep 21, 2021 |
| DOI | 10.2147/OTT.S316288 |
| Devices mentioned | 211800 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1